INS and polycystic ovary syndrome: Similarly, MI and/or DCI supplementation in women with polycystic ovary syndrome (PCOS), who frequently present with insulin resistance and compensatory hyperinsulinaemia, reduced circulating insulin levels, improved systemic glucose tolerance and/or insulin sensitivity, systolic/diastolic blood pressure and/or circulating lipids (triglycerides and cholesterol) [469,470] and reduced body weight [471], which was associated with improvements in the menstrual cycle across all studies.